Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer

Basit Öğe Kaydı
dc.contributor.authorİçli, Fikri
dc.contributor.authorAkbulut, Hakan
dc.contributor.authorUtkan, Güngör
dc.contributor.authorYalçın, Bülent
dc.contributor.authorDinçol, Dilek
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorDemirkazık, Ahmet
dc.contributor.orcid0000-0002-7451-2786
dc.contributor.orcid0000-0003-1631-5739
dc.date.accessioned2024-04-24T15:59:27Z
dc.date.available2024-04-24T15:59:27Z
dc.date.issued2007
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description38th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 18-21, 2002 -- ORLANDO, FLen_US
dc.description.abstractBackground: In this non-randomized study we aimed to assess the efficacy of the addition of low molecular weight heparin (LMWH) to gemcitabine (GEM) plus cisplatinum (CDDP) combination chemotherapy on survival by prevention of thromboembolic complications in patients with advanced pancreatic cancer (APC). Patients and Methods: Between November 1999 and February 2004, 69 consecutive patients with APC were treated with GEM (800 Mo,/M2, day 1, day 8) plus CDDP (35 mg/m(2), day 1, day 8) every 21 days +/- LMWH (nadroparine calcium, 2,850 IU/day until disease progression). Ten out of 35 patients in LMWH group and 10 out of 34 patients in chemotherapy alone group had primary inoperable locally advanced disease and the rest of the patients had metastatic disease. Results: Total response rate was 58.8% (11.7% CR) for the patients treated with LMWH and 12.1% for those treated without LMWH (P = 0.0001). LMWH group had a better median time to progression (TTP) and survival when compared to control group (7.3 vs. 4.0 months, P = 0.0001; 13.0 vs. 5.5 months, P = 0.0001). The toxicity was similar and acceptable in both groups. Conclusion: Addition of LMWH to GEM plus CDDP combination significantly improved the response and survival in patients with APC and the current schedule deserves to be tested in phase III trials. J. Surg. Oncol. 2007;95:507-512. (C) 2006 Wiley-Liss, Inc.en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.citationİçli, F., Akbulut, H., Utkan, G., Yalçın, B., Dinçol, D., Işıkdoğan, A. ve diğerleri. (2007). Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. Journal of Surgical Oncology, 95(6), 507-512.
dc.identifier.doi10.1002/jso.20728
dc.identifier.endpage512en_US
dc.identifier.issn0022-4790
dc.identifier.issn1096-9098
dc.identifier.issue6en_US
dc.identifier.pmid17192920en_US
dc.identifier.scopus2-s2.0-34248202262en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage507en_US
dc.identifier.urihttps://doi.org/10.1002/jso.20728
dc.identifier.urihttps://hdl.handle.net/11468/14078
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1002/jso.20728
dc.identifier.volume95en_US
dc.identifier.wosWOS:000246167800012
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorIşıkdoğan, Abdurrahman
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Surgical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdvanced pancreatic carcinomaen_US
dc.subjectLow Molecular weight heparinen_US
dc.subjectCisplatinen_US
dc.subjectGemcitabineen_US
dc.subjectNadroparineen_US
dc.titleLow molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic canceren_US
dc.typeConference Objecten_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.pdf
Boyut:
96.77 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu